Spelling suggestions: "subject:"HIV anda treatment."" "subject:"HIV ando treatment.""
21 |
Synthesis and characterization of bimetallic silver and platinum nanoparticles as electrochemical sensor for nevirapine, an anti-HIV drugOluoch, Okumu Fredrick January 2016 (has links)
Thesis (DTech (Chemistry))--Cape Peninsula University of Technology, 2016. / Bimetallic silver-platinum (Ag-Pt) nanoparticles (NPs) were synthesized via simultaneous reduction of varying mole fractions of metal precursors H2PtCl6.6H2O and AgNO3 by sodium citrate. Kinetics rates of were as follows; Ag NPs (0.079 s-1), Ag-Pt NPs 1:1 (0.082 s-1) and Pt NPs (0.006 s-1). The UV visible spectrum of Ag NPs exhibited a characteristic absorption band while Pt NPs and Ag-Pt bimetallic NPs exhibited no absorption peaks. Successful formation of both monometallic and bimetallic NPs was confirmed via transmission electron microscopy (TEM); selected area electron diffraction (SAED) and energy dispersive X-ray (EDX) analysis. TEM images depicted core-shell arrangement in the bimetallic (BM) NP ratios (1:1, 1:3 and 3:1) with an average particle size of 21 nm. The particle size trend where monometallic Ag NPs (60 nm) > Pt NPs (2.5 nm) while in the BM ratios Ag-Pt NPs 1:1 (25 nm) > Ag-Pt NPs 1:3 (20.7 nm). X-ray diffraction (XRD) patterns depicted crystallinity in all the synthesized NPs with confirmation of the face centred cubic structure formation. Transducers were fabricated by drop casting the nanoparticless on the glassy carbon electrode (GCE) and their electrochemical properties studied via cyclic voltammetry (CV). High diffusion coefficient (D) and surface coverage reported were Ag NPs (6.70 cm2 s-1, 54.49 mol cm-2 ) and Ag-Pt NPs 1:1 (0.62 cm2 s-11.85 mol cm-2). Electrochemical band gaps ranged from 1.45 to 1.70 eV while the Tauc’s model band gaps of nanoparticles were found in the range of 2.48 to 3.84 eV. These band gaps were found to be inversely proportional to particle size, which was attributed to the quantum confinement effect. Both optical and electrochemical band gap portrayed similar trend as well as an increase in the BM NP relative to monometallics. These nanoparticles band gaps are within semiconductor range for most materials. The electrochemical behaviour and surface characteristics were studied using 0.1 M PBS solution by scan rates variations for the diffusion coefficient determination of modified electrodes which ranged from 0.62 to 6.10 x 10-5 cm2 s-1. Laviron’s approach for parameters such as apparent charge transfer rate constant, ks, and charge transfer coefficient, α, for electron transfer between NPs and GCE were investigated using CV. The values of electron-transfer coefficients ranged from 0.1 to 0.7 while the charge transfer rate constant values ranged from 0.74 to 31.13 s-1.
|
22 |
African indigenous methods of health promotion and HIV/AIDS preventionDlamini, Busisiwe Precious January 2006 (has links)
Submitted in partial completion for the degree of PHD in Community Psychology in the University of Zululand, 2006. / HIV/AIDS is the current century's challenge that stares humanity in the eye. The socio-political, economic, spiritual and philosophical dimensions of our society have to face up to this challenge. This brings one to the conclusion that HIV/AIDS is a national disaster and should be dealt with as such. In other words, interventions geared towards combating this epidemic should address all the spheres mentioned above. The main purpose of this study then was to investigate the role of indigenous healers in combating HIV and AIDS.
The rationale for looking at the role of indigenous healers was to ensure that their role is highlighted for a joint effort that is necessary for the advocacy, awareness, education, care and medical intervention which is necessary to combat the HIV/AIDS crisis. This challenge goes as far as involving non-medical professionals and stakeholders in the fight against HIV/AIDS.
Focus group interviews and individual interviews were conducted with indigenous healers in the Gauteng and North West provinces. The results were analysed thematically. The results are presented in relation to the questions which were posed.
The results reflected that traditional healers have demonstrated that they can make a very important contribution to the treatment of HIV/AIDS. However, they feel that they are not receiving a fair opportunity to
demonstrate their knowledge and expertise in treating HIV and AIDS. They also lack support from the public, from government policy, and from the modem medical fraternity.
There have been efforts by the Minister of Health to incorporate traditional healing and traditional medicine as part of a holistic approach to the treatment and containment of HIV. This strengthens holistic health care ensuring the advocacy, awareness, education, care and medical intervention which is necessary to combat the HIV/AIDS crisis.
Traditional healers need support and recognition from the public, the government and the modem medical fraternity. It was also evident from the results that the indigenous healers were very willing to co-operate with biomedical practitioners as shown in the statement below.
Traditional healers reported that they did not routinely test their patients for HIV as they had no means of doing that. They were legally required to send their patients for testing through modem medical procedures. Most healers also said that they preferred their patients to be checked using modem medicine, and thereafter they would treat them accordingly. This is because they currently relied only on their ancestors to show them when the patient was positive. What is important to note is that these healers said that the disease was not presented to their bones as HIV/AIDS, but
that they were only shown the known symptoms of HIV and then were able to deduce that the person was HIV positive.
|
23 |
A health technology assessment of HIV counseling and testing technologiesHutchinson, Angela Blair 07 June 2004 (has links)
No description available.
|
24 |
Pre-treatment preparation and loss-to-care of adults living with HIV from an antiretroviral therapy clinic in Durban, KwaZulu-Natal.Nixon, Krystal-Lee. January 2011 (has links)
Introduction. The demand for comprehensive Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) services is greater than the available supply, particularly for the provision of antiretroviral therapy. The resulting bottleneck in service delivery has considerable implications for people living with HIV and for resource management. Aim. The purpose of this research was to investigate loss-to-care and associated variables of adult HIV-infected people who were eligible for antiretroviral therapy, from July 2004 to December 2007 at Sinikithemba HIV Clinic in Durban, KwaZulu-Natal. Methods. An observational descriptive and analytic cohort study design was used. Secondary data sourced from Sinikithemba were collated. All HIV-infected adults, 15 years and older when registered on the TrakCare database, who were eligible for antiretroviral therapy were included in the study. Data were extracted to describe the preparation of HIV infected adults who were eligible for antiretroviral therapy. Variables were first summarised and described before the confirmatory analytic steps were taken to measure associations at the p<0.05 significance level. Results. Of the 10 424 HIV-infected adults registered at Sinikithemba, 5470 (52%) were eligible for antiretroviral therapy from July 2004 to December 2007 and 2979 (54%) of these were lost to care prior to initiating antiretroviral therapy. Six exposure variables were significantly associated with this loss-to-care, (gender, baseline CD4 count, pre-eligibility care, antiretroviral therapy delay, preparation step and waiting time). These variables remained significantly associated with loss-to-care even after controlling for confounding with logistic regression. Discussion and Recommendations. With the rapid scale-up of antiretroviral therapy programmes, the outcome of those people living with HIV lost to care before commencing therapy have not been adequately documented. This large cohort enrolled over three-and-a-half years demonstrates that the loss-to-care prior to initiation of antiretroviral therapy is a significant problem that needs to be further investigated. Focusing retention strategies at the pre-antiretroviral therapy stage of HIV care will improve overall programme outcomes. / Thesis (M.Med.)-University of KwaZulu-Natal, Durban, 2011.
|
25 |
Pharmacokinetic herb-drug interaction study of selected traditional medicines used as complementary and alternative medicine (CAM) for HIV/AIDSAwortwe, Charles 03 1900 (has links)
Thesis (DMed)--Stellenbosch University, 2015 / ENGLISH ABSTRACT: Introduction
The increasing intake of traditional medicines among HIV/AIDS patients in sub-Saharan Africa needs urgent consideration by clinicians and other healthcare providers since the safety of such medications are unknown. The pharmacokinetic parameters - Absorption, Distribution, Metabolism and Elimination (ADME) play important role in the safety evaluation of drugs, thus implicating drug metabolizing enzymes and transporters as critical indicators for herb-drug interactions. The objective of this study was to evaluate the risk potential of seven herbal medicines commonly consumed by HIV/AIDS patients for drug interactions applying in vitro models. In this study, inhibition and induction effects of the herbal medicines on cytochrome P450s (CYPs) 1A2, 2C9, 2C19, 2D6 and 3A4 as well as P-glycoprotein (P-gp) were investigated.
Methods
Herbal medicines – Lessertia frutescens, Hypoxis hemerocallidea, Kalanchoe integra and Taraxacum officinale were sourced from Medico Herbs, South Africa were identified by experts from Compton Herbarium, South African National Biodiversity Institute, Cape Town. Moringa oleifera, Echinacea purpurea and Kalanchoe crenata were obtained from the repository of the National Centre for Natural Product Research (NCNPR), University of Mississippi, USA. Reversible inhibitory effect of aqueous and methanol herbal extracts were evaluated in recombinant CYPs applying the fluorescent metabolites at specified excitation/emission wavelengths; CYP1A2 (3-cyano-7-hydroxycoumarin (CHC); 405/460 nm), CYP2C9, CYP2C19 and CYP3A4 (7-hydroxy-4-(trifluoromethyl)-coumarin (HFC); 405/535 nm) and CYP2D6 (7-hydroxy-4-(aminomethyl)-coumarin (HAMC); 390/460 nm). Comparative studies in human liver microsomes (HLM) and recombinant CYPs were conducted to investigate the inhibitory effect of methanol herbal extracts and fractions on 6β testosterone hydroxylation activity. Time dependent inhibitory (TDI) effect of the herbal extracts were evaluated applying the IC50 shift fold, normalized ratio and the NADPH-, time- and concentration-dependent approaches. Influence of herbal extracts on metabolic clearance of testosterone was assessed in both HLM and human hepatocytes. The effects of each herbal extract on expression of CYP1A2, CYP3A4 and MDR1 genes were evaluated in activated human pregnane X receptor (PXR) co-transfected HepG2 cells. Finally, the inhibitory effect of herbal extracts on P-gp was assessed using the calcein-acetoxymethyl ester (calcein-AM) uptake and the digoxin radiolabelled substrates in MDCKII-MDRI cells.
Results
The aqueous extracts of Moringa oleifera, Kalanchoe integra, Kalanchoe crenata, Echinacea purpurea and Lessertia frutescens demonstrated high risk of in vivo inhibition on CYPs 3A4 and 1A2 with Cmax/Ki >1.0. Methanol extracts of these herbal medicines also indicated potential risk of reversible drug interaction. The methanol extracts of M. oleifera, K. crenata and L. frutescens showed strong TDI effect on CYP3A4 with IC50 shift fold >1.5 and normalised ratio <0.7. Moringa oleifera intermediately reduced intrinsic clearance of testosterone in human hepatocytes (2 ≤ AUC ratio ≤ 5) when scaled up to humans. Methanol extracts of Echinacea purpurea up-regulated the expression of CYP1A2, CYP3A4 and MDR1 genes in activated PXR. Kalanchoe crenata and Echinacea purpurea indicated strong inhibition on P-gp by reducing transport of digoxin across hMDR1-MDCKII cell monolayer from basolateral to apical with IC50 values of 18.24 ± 2.52 μg/mL and 24.47 ± 4.97 μg/mL, respectively.
Conclusion
The herbal medicines especially M. oleifera, K. integra and E. purpurea have the potential to cause herb-drug interaction in vivo if sufficient hepatic concentration is achieved in humans. / AFRIKAANSE OPSOMMING: Inleiding
Die verhoogde inname van tradisionele medisynes onder MIV/VIGS-pasiënte in sub-Sahara-Afrika verg dringend oorweging deur klinici en ander gesondheidsorgverskaffers, aangesien die veiligheid van sodanige medikasies onbekend is. Die farmakokinetiese parameters – Absorpsie, Distribusie, Metabolisme en Eliminasie (ADME) – speel ’n belangrike rol by die veiligheidsevaluering van geneesmiddels, en impliseer gevolglik geneesmiddel-metaboliserende ensieme en vervoerders as kritiese indikators vir krui-geneesmiddel-interaksies (HDI). Die oogmerk van hierdie studie is om die risikopotensiaal van sewe kruiemedisynes wat algemeen deur MIV/VIGS-pasiënte geneem word, vir geneesmiddel-interaksies te evalueer deur in vitro-modelle te gebruik. In hierdie studie is die inhiberings- en induseringsuitwerkings van die kruiemedisynes op sitochroom P450’s (verkort na CYP’s) 1A2, 2C9, 2C19, 2D6 en 3A4, sowel as P-glikoproteïen (P-gp), ondersoek.
Metodes
Kruiemedisynes – Lessertia frutescens, Hypoxis hemerocallidea, Kalanchoe integra en Taraxacum officinale – is van Medico Herbs, Suid-Afrika, bekom en deur kundiges van die Compton-herbarium, by die Suid-Afrikaanse Nasionale Biodiversiteitsinstituut, Kaapstad, geïdentifiseer. Moringa oleifera, Echinacea purpurea en Kalanchoe crenata is van die bewaarplek van die Nasionale Sentrum vir Natuurlike Produknavorsing (NCNPR) aan die Universiteit van Mississippi in die VSA verkry. Die omkeerbare inhiberende uitwerking van kruie-ekstrakte in water en metanol is in rekombinante CYP’s geëvalueer deur die gebruik van die fluoresserende metaboliete op gespesifiseerde opwekkings-/emissiegolflengtes; CYP1A2 (3-siaan-7-hidroksikumarien (CHC); 405/460 nm), CYP2C9, CYP2C19 en CYP3A4 (7-hidroksi-4-(trifluoormetiel)-kumarien (HFC); 405/535 nm) en CYP2D6 (7-hidroksi-4-(aminometiel)-kumarien (HAMC); 390/460 nm). Vergelykende studies van menslikelewermikrosome (HLM) en rekombinante CYP’s is uitgevoer om die inhiberende uitwerking van metanolkruie-ekstrakte en -fraksies op 6β-testosteroonhidroksileringsaktiwiteit te ondersoek. Die tydafhanklike inhiberende uitwerking (TDI) van die kruie-ekstrakte is geëvalueer deur gebruikmaking van die IC50-verskuiwingsvou-, die genormaliseerdeverhoudings- en die NADPH-, tyd- en konsentrasieafhanklike benaderings. Die invloed van kruie-ekstrakte op metaboliese testosteroonverheldering is in beide HLM en menslike hepatosiete geëvalueer. Die uitwerkings van elke kruie-ekstrak op die uitdrukking van CYP1A2-, CYP3A4- en MDR1-gene is in geaktiveerde menslike pregnaan-X-reseptor(PXR)-, ko-getransfekteerde HepG2-selle geëvalueer. Laastens is die inhiberende uitwerking van kruie-ekstrakte op P-gp geëvalueer, met gebruikmaking van die kalsien-asetoksimetiel-ester (kalsien-AM)-opname en die digoksien- radiogemerkte substrate in MDCKII-MDRI-selle.
Resultate
Die ekstrakte in water van M. oleifera, K. integra, K. crenata, E. purpurea en L. frutescens het ’n hoë risiko van in vivo-inhibering op CYP’s 3A4 en 1A2 met Cmaks/Ki >1.0 getoon. Ekstrakte van hierdie kruiemedisynes in metanol het verder potensiële risiko van omkeerbare geneesmiddelinteraksie getoon. Die ekstrakte van M. oleifera, K. crenata en L. frutescens in metanol het sterk TDI-uitwerking op CYP3A4 met IC50-verskuiwingsvou >1.5 en genormaliseerde verhouding <0.7 getoon. M. oleifera het intermediêre vermindering van intrinsieke testosteroonverheldering in menslike hepatosiete (2 ≤ AUC verhouding ≤ 5) tot gevolg wanneer die skaal na mense verhoog word. Ekstrakte van E. purpurea in metanol het die uitdrukking van CYP1A2-, CYP3A4- en MDR1-gene in geaktiveerde PXR opgereguleer. K. crenata en E. purpurea het sterk inhibering van P-gp getoon deur die vervoer van digoksien deur die hMDR1-MDCKII-selmonolaag van basolateraal tot apikaal met IC50-waardes van onderskeidelik 18.24 ± 2.52 μg/mL en 24.47 ± 4.97 μg/mL te verminder.
Gevolgtrekking
Kruiemedisynes, veral M. oleifera, K. integra en E. purpurea, het die potensiaal om HDI in vivo te veroorsaak indien voldoende hepatiese konsentrasie by mense bereik word.
|
26 |
Drug-drug interactions between antiretrovirals and fluconazole in HIV-infected patientsFouche, Desire 03 1900 (has links)
Thesis (MScMedSc)--Stellenbosch University, 2012. / ENGLISH ABSTRACT: Background: HIV-positive patients have a significantly weakened immune system which
makes them highly susceptible for opportunistic infections, requiring additional treatment.
Cryptococcal meningitis and oropharyngeal candidiasis are treated with oral fluconazole. A
great potential for drug-drug interactions (DDIs) between fluconazole and antiretrovirals
(ARVs), efavirenz, nevirapine, and lopinavir/ritonavir, exists due to interference in common
metabolic pathways. The outcome may result in the development of adverse drug reactions
or drug resistance and treatment failure.
Aim: The primary aim of this thesis was to evaluate the effect of fluconazole on the
pharmacokinetics of efavirenz, nevirapine and lopinavir/ritonavir in HIV-infected patients
diagnosed with cryptococcal meningitis or oropharyngeal candidiasis.
Methods: A prospective study was conducted in 80 HIV-positive, treatment experienced
adults (≥18 years old) treated in three different outpatient clinics in the Western Cape region.
Patients were subdivided according to ARV regimen and the use of fluconazole. A sparse
sampling design was used and corresponding ARV serum concentrations were determined by
established HPLC and GC methods. Fluconazole serum concentrations were determined by a
newly developed HPLC method. Patient characteristics, concomitant medications, clinical
test data and ARV serum concentrations were included in a NONMEM generated, onecompartment,
open pharmacometric model with first order elimination to detect any drugdrug
interactions between fluconazole and the studied ARVs. The secondary outcome was to
establish which patient characteristics influence ARV pharmacokinetics.
Results: From 80 outpatients, a total of 276 ARV serum samples (137 efavirenz, 67
nevirapine and 72 lopinavir) were collected for pharmacokinetic evaluation. Efavirenz
clearance was correlated with race and concomitant use of rifampicin. No significant
covariates were established in the nevirapine model. In the lopinavir model, concomitant use
of clotrimazole and the antituberculosis combination isoniazid, pyrazinamide and rifampicin
were identified as significant covariates.
Discussion: No significant effects of fluconazole on the pharmacokinetics of any of the
studied ARVs were observed. Varying efavirenz plasma concentrations in different ethnic
populations may be due to differences in gene expression particularly CYP2B6. Coloured patients had significantly lower efavirenz serum concentrations (56.8% decrease in
clearance), which has not been previously described in the South African context. Although
gender was not a significant covariate in the nevirapine model, female patients tended to have
higher nevirapine serum concentrations. TB treatment in all patients receiving lopinavir
consisted of a combination of isoniazid, pyrazinamide and rifampicin, each with different
effects on CYP isoenzymes. The exact contributing factor of each drug in the ultimate
decrease in lopinavir clearance (46.4%) can therefore not be established.
Conclusions: Given the limitations of the sample size in the present study, no statistical
significant effect of fluconazole on the pharmacokinetics of the investigated ARVs could be
demonstrated. A retrospective analysis of the data showed various co-factors that influence
the pharmacokinetics of the investigated ARVs. This data needs to be confirmed in a
prospective study as the identified covariates are appropriate in the management of HIVinfected
patients in the South African context. / AFRIKAANSE OPSOMMING: Agtergrond: HIV-positief pasiënte het ‘n aansienlike verswakte immuunstelsel, wat hul
hoogs vatbaar tot opportunistiese infeksies maak, en dus, addisionele behandeling benodig.
Cryptococcal meningitis en orofaringeale kandidiase word met orale flukonasool behandel.
As gevolg van middeling in algemene metaboliese paaie is daar ‘n groot moontlikheid van
middel-middel interaksies tussen flukonasool en die antiretrovirale (ARV) middels,
efavirenz, nevirapine, en lopinavir/ritonavir. Die uitkomste hiervan mag tot die ontwikkeling
van nadelige middel-middel interaksies of middelweerstandigheid en mislukte behandeling
lei.
Doel: Die primêre doel van hierdie tesis was om die effek van flukonasool op die
farmakokinetika van efavirenz, nevirapine en lopinavir/ritonavir in HIV geïnfekteerde
pasiënte met gediagnoseerde cryptococcal meningitis en orofaringeale kandidiase te evalueer.
Metodes: Die studie was met 80 HIV-positief, behandeling-ervare volwassenes (≥18 jaar)
onderneem. Voorafgenoemde was in drie verskillende buitepasiëntklinieke in die Wes-Kaap
behandel. Pasiënte was volgens ARV regimen en die gebruik van flukonasool, of dan nie,
verder verdeel. ‘n Beperkte steekproef ontwerp was gebruik, en ooreenstemmende ARV
serum konsentrasies is deurgevestigde HPLC en GC metodes vasgestel. Flukonasool serum
konsentrasies was deur ‘n nuutontwikkelde HPLC metode vasgestel. Pasiëntkenmerke,
gepaardgaande medikasie, kliniesetoets data en ARV serum konsentrasies was by ‘n
NONMEM genereerde, een-kompartement, oop farmakometriese model met eerste orde
eliminasie ingesluit om enige middel interaksies tussen flukonasool en die bestudeerde ARVs
op te tel. Die sekondêre uitkomste was om vas te stel watter pasiënt kenmerke ARV
farmakokinetika beïnvloed.
Resultate:Uit 80 buitepasïente was ‘n totaal van 276 ARV serum monsters (137 efavirenz,
67 nevirapine en 72 lopinavir) vir farmakokinetiese evaluasie gekollekteer. Efavirenz
opruiming was met ras gekorreleer asook gepaardgaande gebruik van rifampisien. Geen
betekenisvolle ko-variante was in die nevirapine model vasgestel nie. In die lopinavir model
het die gepaardgaande gebruik van clotrimazole en die anti-tuberkulose kombinasie
isoniazied, pyrazinamied en rifampisien, lopinavir opruiming verminder.
Bespreking: In hierdie studie is geen betekenisvolle effekte van flukanosool op die
farmakokinetika van enige van die bestudeerde ARVs waargeneem nie. Afwisselende
efavirenz plasma konsentrasies in verskillende etniese populasies mag aan verskille in
geenuitdrukking, veral CYP2B6, toegeskryf word. Kleurling pasïente het betekenisvolle
verlaagde efavirenz serum konsentrasies getoon (56.8% verlaging in opruiming). Hierdie
bevinding is nog nooit voorheen in die Suid-Afrikaanse konteks beskryf nie. Alhoewel geslag
nie ‘n beduidende ko-variant in die nevirapine model was nie, het vroulike pasïente geneig
om hoer nevirapine serum konsentrasies te hê. TB behandeling, in alle pasïente wat lopinavir
ontvang het, het uit die volgende kombinasie bestaan: isoniazied, pyrazinamied en
rifampisien, elk met hul eie effekte op CYP isoensieme. Die presiese bydra van elke middel
in die uiteindelike verlaging (46.4%) in lopinavir opruiming kan dus nie vasgestel word nie.
Gevolgtrekking: Gegewe die beperkings van die steekproef in die huidige studie, kon geen
statistiese beduidende effek van flukonazool op die farmakokinetika van die betrokke ARVs
gedemonstreer word nie. ‘n Retrospektiewe analise van die data het gewys dat verskeidene
ko-faktore die farmakokinetika van die betrokke ARVs beïnvloed. Hierdie data moet in ‘n
prospektiewe studie bevestig word omdat die geidentifiseerde covariates die bestuur van
MIV-positiewe pasiente in die Suid-Afrikaanse konteks te verbeter.
|
27 |
Counterfeiting of HIV/AIDS medicines : implications for global epidemic : recommendations for workplace programsNorris, Gerard Benedict 04 1900 (has links)
Thesis (MPhil)--Stellenbosch University, 2005. / ENGLISH ABSTRACT: multiple therapeutic categories of medicines
have been increasingly targeted for counterfeiting.
According to Van Niekerk [Van Niekerk, Anton. (2001). Moral and social complexities
of AIDS in Africa. University of Stellenbosch], “it is commonplace to identify and
bewail a plethora of problems in the developing world generally, and in Africa in
particular. Poverty, illiteracy, famine, political instability, natural disasters, and
many more misfortunes dominate the history of this part of the world over the past
50 years. It was therefore adding uncalled (undeserved?) insult to already
overwhelming injury when HIV/AIDS visibly struck the world since mid-1980. In
spite of all the other calamities that Africa has to deal with, it nevertheless is no
exaggeration to claim that HIV/AIDS nowadays constitutes the most serious health
and social crisis and challenge that has ever befallen the continent”. Similar patterns
involving HIV/AIDS are now emerging on other continents.
One objective of this recent research study was to explore possible relationships between
the growing scourges of the worldwide counterfeiting of medicines and parallels with the
expanding global HIV/AIDS pandemic - as well as to examine potential relationships and
risks associated with other diseases that have been observed to have ‘special associations’
with HIV and AIDS [e.g. sexually transmitted infections (STI’s), Tuberculosis (TB) and
Malaria] - and possible impact on the “World of Work”. A second and important
objective was to develop Recommendations for Workplace Programs. The information
gathered has also been used to propose future studies regarding HIV/AIDS and
counterfeiting.
In the developing world, antibiotics and anti-parasitic medicines are included among the
counterfeiters’ favorite targets. Strong parallels exist between locations where
counterfeiting of medicines is taking place/product being distributed/sold and where
HIV/AIDS is most prevalent and/or where the epidemic is expanding progressively.
Counterfeiting of medicines used for treating HIV/AIDS raises the possibility of
additional future complications developing in managing other global diseases such as
Malaria and Tuberculosis, not to mention exacerbating the potential for developing
resistance and encouraging mutation of the HI virus itself. It is also noteworthy that
certain medical devices have also been found to be counterfeit.
Global demographics and with particular reference to projected growth rates of
populations of the developing world are of specific relevance to this subject of anticounterfeiting
and medicines used for the treatment of HIV and AIDS. Indeed, next
generations of humanity appear to be at unnecessary risk of being caught up in a
confluence of forces whereby the practice of the counterfeiting of medicines could result
in significant complications and unforeseen consequences regarding management of the
global HIV/AIDS crisis. Following the research, recommendations for workplace
programs were developed. The research study concludes with a comprehensive set of
references. / AFRIKAANSE OPSOMMING: Die problamatiek aangaande die vervalsing (namaak) van medisyne word nou wereldwyd
ervaar en het ‘n impak op beide die geindustrialiseerde en die ontwikkelende wereld.
Menige medisyne in terapeutiese kategoriee is tot op hede as vervals geidentifeseer, met
die direkte resultaat dat hulle ‘n minemale of geen terapeutiese uitwerking het nie. Wat
nog erger is, is dat hierdie middels uiters gevaarlik is om te gebruik en selfs
lewensgevaarlik kan wees. Dit is van groot betekenis dat ook medisyne wat bestem is om
persone met HIV/VIGS te behandel, as vervals aangetoon is – en soedoende tot nog toe
onbekende gevolge vir pasiente, die werkomgewing en ongekende risiko’s vir wereldwye
gesondheidsorg en internasionale veiligheid en sekuriteit inhou. In hierdie studie word
die onderwerp in taamlike besonderhede bestudeer en daar word afgesluit met
aanbevelings oor programme in die werkplek wat ontwerp is om sorg en ondersteuning te
bied aan werkers met HIV/VIGS. Verdere studie word ook aanbeveel om die tergende
probleme wat volg op die vervalsing van medisyne in die behandling van persone met
HIV/VIGS, en die implikasies hiervan, die hoof te bide.
|
28 |
A reinforcement learning design for HIV clinical trialsParbhoo, Sonali 30 July 2014 (has links)
A dissertation submitted to the Faculty of Science, University of the Witwatersrand, Johannesburg, in fulfilment of the requirements for the degree of Master of Science. Johannesburg, 2014. / Determining e ective treatment strategies for life-threatening illnesses such as HIV is
a signi cant problem in clinical research. Currently, HIV treatment involves using
combinations of anti-HIV drugs to inhibit the formation of drug-resistant strains. From
a clinician's perspective, this usually requires careful selection of drugs on the basis of an
individual's immune responses at a particular time. As the number of drugs available for
treatment increases, this task becomes di cult. In a clinical trial setting, the task is even
more challenging since experience using new drugs is limited. For these reasons, this
research examines whether machine learning techniques, and more speci cally batch
reinforcement learning, can be used for the purposes of determining the appropriate
treatment for an HIV-infected patient at a particular time. To do so, we consider using
tted Q-iteration with extremely randomized trees, neural tted Q-iteration and least
squares policy iteration. The use of batch reinforcement learning means that samples
of patient data are captured prior to learning to avoid imposing risks on a patient.
Because samples are re-used, these methods are data-e cient and particularly suited to
situations where large amounts of data are unavailable. We apply each of these learning
methods to both numerically generated and real data sets. Results from this research
highlight the advantages and disadvantages associated with each learning technique.
Real data testing has revealed that these batch reinforcement learning techniques have
the ability to suggest treatments that are reasonably consistent with those prescribed
by clinicians. The inclusion of additional state variables describing more about an
individual's health could further improve this learning process. Ultimately, the use of
such reinforcement learning methods could be coupled with a clinician's knowledge for
enhanced treatment design.
|
29 |
Synthesis of peptidomimetic compounds as potential anti HIV and malaria agentsZimuwandeyi, Memory 14 May 2015 (has links)
A thesis submitted to the Faculty of Science University of the Witwatersrand
Johannesburg in fulfillment for the requirements of the degree of Master of Science.
14 May 2015. / Peptidomimetic compounds have been shown to exhibit both anti-HIV and anti-malarial activity. A multicomponent reaction was used to create a library of peptidomimetic compounds with an α-hydroxy-β-amino acid unit. The Passerini reaction between an aldehyde, carboxylic acid and isocyanide was used to prepare compounds containing both ester and amide functionalities. These compounds were then subjected to a deprotection-acyl migration strategy giving rise to the target compounds. This approach, known as the Passerini Amine Deprotection Acyl Migration (PADAM) sequence was successfully used to create a library of novel peptidomimetic compounds. From this library, 22 compounds were tested for activity against HIV and malaria.
The Passerini reaction gives rise to a product containing a new stereogenic centre, and as the starting aldehyde used (N-Boc-phenylalaninal) has a stereogenic centre, the products were isolated as a mixture of diastereomers. Our research was also focused on finding ways of influencing the stereoselectivity of the reaction and the separation of the resulting diastereomers. The diastereomeric ratio of the Passerini products was found to be approximately 2:1 for all the reactions performed. This ratio could be modified slightly when using certain carboxylic acids and isocyanides that were either very bulky or had a stereogenic centre.
Attempts to enzymatically resolve the diastereomeric products were not successful after trials using a library of 25 lipase enzymes. However, use of preparative HPLC enabled the successful separation of most of the diastereomeric mixtures, affording compounds with high purity. X-ray crystallography enabled us to identify the major diastereomers as having the R,S configuration, whilst the minor diastereomers had the S,S configuration at the two stereogenic centres.
A possible explanation for the observed stereoselectivity is based on the Felkin-Anh chelation control model. It suggests that mono-protected amino aldehydes follow a chelation controlled mechanism in nucleophilic addition reactions. Chelation occurs, albeit in the form of hydrogen bonding, between the NH and carbonyl oxygen.
The library of compounds was tested for activity against both HIV-1 and malaria. Only three compounds showed moderate activity against the malaria parasite, inhibiting parasitic growth by 37-42% at 5 μM respectively. Significantly, all of the active compounds contained an adamantyl moiety. Unfortunately no anti-HIV activity was seen for any of the compounds tested in the HIV-assay.
|
30 |
Genetic variants of d4T drug transporters and dNTP pool regulators, and their association with response to d4T-ARTMoketla, Blessings Marvin January 2017 (has links)
A dissertation submitted to the Faculty of Science, University of the Witwatersrand, Johannesburg, in fulfillment of the requirements for the degree of Master of Science in Genetics.
Johannesburg, South Africa
2017 / Background: Stavudine (d4T) use is associated with the development of sensory neuropathy (SN), several mechanisms may underlie d4T-induced toxicity, including:
(1) Inter-patient genetic variability in the genes modulating the deoxynucleotide triphosphate (dNTP) pool sizes.
(2) Variation in intracellular ARV drug concentrations due to genetic variation in drug transporters.
In our study we examined the genetic variation in four stavudine transporter genes and seven genes regulating the deoxythymidine triphosphate (dTTP) synthesis and their associations with d4T-induced SN or CD4+ T cell count or mtDNA copy number.
Methods: We examined a cohort of HIV-positive South African (SA) adults exposed to d4T, including 143 cases with SN and 120 controls without SN. 26 single nucleotide polymorphisms (SNPs) from the literature were chosen, prioritised on being tagSNPs with minor allele frequency >5% in Kenyan Luhya (a proxy population for the SA Black population); SNP functional effects and suitability for multiplex analysis on the genotyping platform. Genotyping was performed using Sequenom mass spectrometry. A qPCR assay was used to measure the mtDNA copy number. Association of sensory neuropathy, CD4+ T cell count and mtDNA copy number with genetic variants was evaluated using PLINK.
Results: All 26 SNPs were in Hardy-Weinberg equilibrium (HWE) in both the cases and controls. SNP rs8187758 of the SLC28A1 transporter gene and a 3-SNP haplotype ABCG2 were significantly associated with CD4+ T cell count after correction for multiple testing (p = 0.043 and p=0.042 respectively), but were not significant in multivariate testing. No SNP remained significantly associated with SN or mtDNA copy number, after correction for multiple testing.
Conclusion: Variation in genes encoding molecular transporters of d4T may influence CD4+ T cell counts after ART. This study presents a positive step towards achieving personalized medicine in SA. / MT 2018
|
Page generated in 0.0878 seconds